%0 Journal Article
%T Human papillomavirus genotype and prognosis of cervical cancer: Favorable survival of patients with HPV16-positive tumors
%A Akinori Oki
%A Azusa Akiyama
%A Hiroyuki Yoshikawa
%A Koji Matsumoto
%A Mamiko Onuki
%A Manabu Sakurai
%A Nobutaka Tasaka
%A Takeo Minaguchi
%A Toyomi Satoh
%A Yuri Tenjimbayashi
%J Archive of "Papillomavirus Research".
%D 2018
%R 10.1016/j.pvr.2018.10.005
%X The prognostic impact of human papillomavirus (HPV) type on invasive cervical cancer (ICC) was analyzed for 137 women treated for ICC at a single institution between 1999 and 2007. The study subjects were divided into three groups according to HPV genotype: HPV16-positive (n£¿=£¿59), HPV18-positive (n£¿=£¿33), and HPV16/18-negative ICC (non-HPV16/18, n£¿=£¿45). The median follow-up time was 102.5 months (range, 5¨C179). The 10-year overall survival (10y-OS) rates in women with FIGO stage I/II disease were similar among HPV genotypes: 94.7% for HPV16 (n£¿=£¿39), 95.2% for HPV18 (n£¿=£¿26), and 96.4% for non-HPV16/18 (n£¿=£¿29). However, the 10y-OS rates in women with FIGO stage III/IV tumors were 73.7% for HPV16 (n£¿=£¿20), 45.7% for HPV18 (n£¿=£¿7), and 35.7% for other types (n£¿=£¿16), with significantly higher survival in HPV16-positive compared with HPV16-negative ICC (10y-OS; 73.7% vs. 39.5%, P£¿=£¿0.04). This difference in FIGO stage III/IV tumors remained significant after adjusting for age and histology (hazard ratio 0.30, 95% confidence interval 0.09¨C0.86, P£¿=£¿0.02). These results suggest that detection of HPV16 DNA may be associated with a favorable prognosis in patients with FIGO stage III/IV ICC. Given that most women with FIGO stage III/IV tumors received concurrent chemoradiotherapy, this finding may imply that HPV16-positive tumors are more chemoradiosensitive
%K Cervical cancer
%K Human papillomavirus (HPV)
%K Prognosis
%K Radiosensitivity
%K Survival
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218653/